Valve-in-valve transcatheter aortic valve replacement (TAVR) may be a beneficial therapeutic alternative to reoperation in patients with failed aortic bioprostheses, according to the results of the PARTNER II Valve-in-Valve Registry trial, presented Oct. 15 at TCT 2015.

John G. Webb, MD, FACC, and Danny Dvir, MD, et al., evaluated the safety and efficacy of valve-in-valve TAVR with the SAPIEN XT in patients with failed surgical bioprosthetic valves, with the primary endpoint of one-year mortality. Patients included in the trial had symptomatic severe stenosis or regurgitation of a surgical aortic tissue valve and were at high-risk for reoperation. A majority of patients (95.5 percent) were categorized as class 3 or 4 on the New York Heart Association’s (NYHA) heart failure functional classification at baseline.

The results of the study demonstrated the benefits of valve-in-valve TAVR using the SAPIEN XT in this patient population. At one-year follow-up, all-cause mortality was 13.4 percent, while 88 percent were either class 1 or 2 in the NYHA’s functional classification.

The authors of the study note that valve-in-valve TAVR “has emerged as a viable alternative for patients with failing surgical bioprosthetic valves.”

Keywords: Transcatheter Cardiovascular Therapeutics, Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis Implantation, Registries, Bioprosthesis, Constriction, Pathologic, Heart Failure, Reoperation, Transcatheter Aortic Valve Replacement

< Back to Listings